AstraZeneca’s COVID-19 vaccine candidate enters late-stage study in US

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

AstraZeneca Plc said on Monday it began to enroll 30,000 participants aged above 18 in a late-stage study to evaluate its COVID-19 vaccine candidate, AZD1222.

Participants are being randomized to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine as the saline control, the company said.

ADVERTISEMENT

The study is being funded by the U.S. government, the London-listed company said.

FEATURED STORIES


For more news about the novel coronavirus click here.

What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next

EDITORS’ PICK

MOST READ

<!– Please implement on Entertainment only, remove the twitter handle after the byline in #byline_share

Follow @FMangosingINQ on Twitter

–>

Don’t miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

For feedback, complaints, or inquiries, contact us.

Back To Top